{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:52:47Z","timestamp":1684421567497},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T00:00:00Z","timestamp":1545609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>End-stage renal disease (ESRD) patients even without known cardiovascular (CV) disease have high mortality rates. Whether neurohormonal blockade treatments improve outcomes in this population remains unknown. The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEi\/ARBs), \u03b2-blockers or both in all-cause mortality rates in incident ESRD patients without known CV disease starting renal replacement therapy (RRT) between 2009 and 2015 in the nationwide R\u00e9seau Epid\u00e9miologie et Information en N\u00e9phrologie registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with known CV disease and those who started emergency RRT, stopped RRT or died within 6\u2009months were excluded. Propensity score matching models were used. The main outcome was all-cause mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 13\u00a0741 patients were included in this analysis. The median follow-up time was 24\u2009months. When compared with matched controls without antihypertensive treatment, treatment with ACEi\/ARBs, \u03b2-blockers and ACEi\/ARBs\u2009+\u2009\u03b2-blockers was associated with an event-rate reduction per 100 person-years: ACEi\/ARBs 7.6 [95% confidence interval (CI) 7.1\u20138.2] versus matched controls 9.5 (8.8\u201310.1) [HR 0.76 (95% CI 0.69\u20130.84)], \u03b2-blocker 7.1 (6.6\u20137.7) versus matched controls 9.5 (8.5\u201310.2) [HR 0.72 (0.65\u20130.80)] and ACEi\/ARBs\u2009+\u2009\u03b2-blockers 5.8 (5.4\u20136.4) versus matched controls 7.8 (7.2\u20138.4) [HR 0.68 (0.61\u20130.77)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neurohormonal blocking therapies were associated with death rate reduction in incident ESRD without CV disease. Whether these relationships are causal will require randomized controlled trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfy378","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T15:17:17Z","timestamp":1542122237000},"page":"1216-1222","source":"Crossref","is-referenced-by-count":4,"title":["Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers, \u03b2-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study"],"prefix":"10.1093","volume":"34","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique, UMR, CHRU de Nancy, Nancy, France"},{"name":"F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy"},{"name":"Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"C\u00e9cile","family":"Couchoud","sequence":"additional","affiliation":[{"name":"Agence de la biom\u00e9decine, Avenue du Stade-de-France, Saint-Denis-La-Plaine Cedex, France"}]},{"given":"John","family":"Gregson","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, UK"}]},{"given":"Aur\u00e9lien","family":"Tiple","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, CHRU de Clermont-Ferrand, Clermont-Ferrand, France"}]},{"given":"Fran\u00e7ois","family":"Glowacki","sequence":"additional","affiliation":[{"name":"EA 4483-IMPECS-IMPact of Environmental Chemicals on Human Health, Facult\u00e9 de M\u00e9decine\/P\u00f4le Recherche, Univ. Lille, place de Verdun, Lille Cedex, France"}]},{"given":"Gerard","family":"London","sequence":"additional","affiliation":[{"name":"F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy"},{"name":"Department of Nephrology, Hospital Manhes, Fleury-M\u00e9rogis, France and"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique, UMR, CHRU de Nancy, Nancy, France"},{"name":"F-CRIN INI-CRCT Cardiovascular and Renal Clinical Trialists, France, Nancy"}]}],"member":"286","published-online":{"date-parts":[[2018,12,24]]},"reference":[{"key":"2019070203530055400_gfy378-B1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1681\/ASN.2009030282","article-title":"Why is the mortality of dialysis patients in the United States much higher than the rest of the world?","volume":"20","author":"Foley","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2019070203530055400_gfy378-B2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2011.04.004","article-title":"Cardiovascular mortality in the general population versus dialysis: a glass half full or empty?","volume":"58","author":"Sarnak","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2019070203530055400_gfy378-B3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(05)65816-3","article-title":"Cardiovascular disease in patients with chronic renal failure","volume":"348","author":"Wheeler","year":"1996","journal-title":"Lancet"},{"key":"2019070203530055400_gfy378-B4","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2019070203530055400_gfy378-B5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"key":"2019070203530055400_gfy378-B6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/HYPERTENSIONAHA.108.128116","article-title":"Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis","volume":"53","author":"Agarwal","year":"2009","journal-title":"Hypertension"},{"key":"2019070203530055400_gfy378-B7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003648","article-title":"Diagnosis and management of cardiovascular disease in advanced and end-stage renal disease","volume":"5","author":"Bhatti","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2019070203530055400_gfy378-B8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0140-6736(16)31331-9","article-title":"Roadmap for cardiovascular prevention trials in chronic kidney disease","volume":"388","author":"Rossignol","year":"2016","journal-title":"Lancet"},{"key":"2019070203530055400_gfy378-B9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019070203530055400_gfy378-B10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"2019070203530055400_gfy378-B11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2019070203530055400_gfy378-B12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis\u2014a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203530055400_gfy378-B13","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2019070203530055400_gfy378-B14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2011.10.047","article-title":"Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare part D","volume":"59","author":"Frankenfield","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2019070203530055400_gfy378-B15","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1046\/j.1523-1755.2002.00636.x","article-title":"Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study","volume":"62","author":"Foley","year":"2002","journal-title":"Kidney Int"},{"key":"2019070203530055400_gfy378-B16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/ndt\/gfr460","article-title":"Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada","volume":"27","author":"Kitchlu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203530055400_gfy378-B17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203530055400_gfy378-B18","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2019070203530055400_gfy378-B19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/0886022X.2016.1138833","article-title":"A systematic review on randomized control trials on rennin angiotensin aldosterone system inhibitors role in managing hypertension among hemodialysis patients","volume":"38","author":"Aftab","year":"2016","journal-title":"Ren Fail"},{"key":"2019070203530055400_gfy378-B20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203530055400_gfy378-B21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association\u2013European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203530055400_gfy378-B22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/hdi.12571","article-title":"Antithrombotic therapy in end-stage renal disease","volume":"21","author":"Chunduri","year":"2017","journal-title":"Hemodial Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/7\/1216\/28889106\/gfy378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T03:53:48Z","timestamp":1562039628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/7\/1216\/5259249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,24]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,12,24]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy378","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2018,12,24]]}}}